Spots Global Cancer Trial Database for braf
Every month we try and update this database with for braf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy | NCT02957266 | Cervical Cancer | Volumetric Arc ... Interstitial br... Cisplatin Gemcitabine PIK3CA KRAS BRAF RRM1 | 18 Years - 70 Years | The National Center of Oncology, Azerbaijan | |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | NCT05868629 | Rare Unresectab... | Non-investigati... | 6 Years - | Novartis | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors | NCT01582997 | Cancer | GSK2118436 | 20 Years - | GlaxoSmithKline | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | NCT01928940 | Solid Tumours | dabrafenib trametinib | 20 Years - | GlaxoSmithKline | |
| Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | NCT04249843 | Solid Tumor B-Raf Mutation-... | BGB-3245 | 18 Years - | MapKure, LLC | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | NCT01657591 | Melanoma | XL888 Vemurafenib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | NCT04201457 | Low Grade Gliom... High Grade Glio... Low Grade Gliom... | Dabrafenib Trametinib Hydroxychloroqu... | 1 Year - 30 Years | Pediatric Brain Tumor Consortium | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | NCT01512251 | BRAF Mutant Met... | BKM120 Combined... | 18 Years - | University of California, San Francisco | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer | NCT01038037 | Non Small Cell ... | Carboplatin Vinorelbine panitumumab | 18 Years - | Vejle Hospital | |
| A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors | NCT01340846 | Cancer | Warfarin Ketoconazole Gemfibrozil GSK2118436 150m... GSK2118436 75mg | 18 Years - | GlaxoSmithKline | |
| Trametinib With GSK2141795 in BRAF Wild-type Melanoma | NCT01941927 | Melanoma | Trametinib (GSK... GSK2141795 | 18 Years - | University of California, San Francisco | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Cetuximab for Elderly Patients With mCRC | NCT01718808 | Metastatic Colo... | Cetuximab Capecitabine | 70 Years - | Swiss Group for Clinical Cancer Research | |
| A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | NCT06194877 | Colorectal Canc... Pancreatic Duct... Advanced or Met... | BGB-3245 Panitumumab | 18 Years - | MapKure, LLC | |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | NCT04620330 | Non Small Cell ... KRAS Activating... | avutometinib (V... avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| Utility of Novel BRAF Test for Melanoma | NCT01840527 | Melanoma | 18 Years - | Massachusetts General Hospital | ||
| Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies | NCT02626065 | Metastatic Mela... | blood sampling Nivolumab | 18 Years - | Hospices Civils de Lyon | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | NCT04620330 | Non Small Cell ... KRAS Activating... | avutometinib (V... avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | NCT05868629 | Rare Unresectab... | Non-investigati... | 6 Years - | Novartis | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | NCT01562899 | Metastatic Panc... BRAF Mutated Me... | MEK162 AMG 479 | 18 Years - | Pfizer | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | NCT02906059 | Metastatic Colo... | AZD1775 Irinotecan | 18 Years - | NYU Langone Health | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | NCT03013491 | Solid Tumor Lymphoma | CX-072 ipilimumab vemurafenib | 18 Years - | CytomX Therapeutics | |
| Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | NCT02367859 | Ameloblastoma BRAF Gene Mutat... | Dabrafenib Trametinib | 18 Years - | Stanford University | |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | NCT05868629 | Rare Unresectab... | Non-investigati... | 6 Years - | Novartis | |
| Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | NCT01928940 | Solid Tumours | dabrafenib trametinib | 20 Years - | GlaxoSmithKline | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
